Pegylated liposomal doxorubicin monotherapy (Kaposi sarcoma)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Fuente YAML: registro completo
| Componentes | DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN |
|---|
| ID | REG-PLD-KAPOSI |
|---|---|
| Tipo | Esquema terapéutico |
| Situación | reviewed 2026-07-11 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | Ninguna declarada |
Notas
New Regimen entity reusing the existing DRUG-PEGYLATED-LIPOSOMAL- DOXORUBICIN Drug entity. The 20 mg/m² IV q2-3wk Kaposi sarcoma dose and toxicity-management triggers (hold thresholds for PPE, stomatitis, ANC/platelet nadir, LVEF decline) are transcribed directly from that ALREADY-EXISTING Drug entity's `typical_dosing`/`notes` fields (which independently document "Kaposi sarcoma: 20 mg/m² IV every 2-3 weeks" and the hold criteria -- verified by direct read of drugs/pegylated_liposomal_doxorubicin.yaml during independent review) -- not a newly invented figure. Pegylated liposomal doxorubicin is FDA-approved for AIDS-related Kaposi sarcoma (see DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN.regulatory_status.fda. indications_brief). INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 throughout this file (top-level sources, every dose-adjustment, every watchpoint) as the evidentiary support for the dosing/toxicity-management content above. Direct inspection of that source's own KB record (sources/src_nccn_skin_2025.yaml) shows its title is "NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer" and its notes explicitly scope it to basal-cell...
Utilizado por
Enfermedad
DIS-KAPOSI- Sarcoma Kaposi
Indicación
IND-KAPOSI-1L-VISCERAL-PLD- IND-KAPOSI-1L-VISCERAL-PLD